{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=45&state=California", "query": { "state": "California", "city": "Fullerton", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 1113, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=46&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=44&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T11:26:01.986Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05083481", "title": "A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP1570", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Trifluridine + Tipiracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2021-10-19", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 12, "location_summary": "Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05083481" }, { "nct_id": "NCT05156866", "title": "First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Gastric Cancer", "Pancreas Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "TORL-2-307-ADC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TORL Biotherapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2022-02-02", "completion_date": "2027-02-15", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Torrance, California + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156866" }, { "nct_id": "NCT02826603", "title": "Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1114, "start_date": "2016-06-22", "completion_date": "2018-07-09", "has_results": true, "last_update_posted_date": "2019-07-09", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 123, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02826603" }, { "nct_id": "NCT00856986", "title": "The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "liraglutide", "type": "DRUG" }, { "name": "insulin detemir", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 987, "start_date": "2009-03", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2017-03-08", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 60, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Encino", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Inglewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00856986" }, { "nct_id": "NCT03368859", "title": "A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil - bolus", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Fluorouracil - infusion", "type": "DRUG" }, { "name": "ABT-165", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2018-03-20", "completion_date": "2019-12-18", "has_results": true, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 46, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 39 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03368859" }, { "nct_id": "NCT02449031", "title": "Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pseudomonas Aeruginosa in Cystic Fibrosis" ], "interventions": [ { "name": "TOBI® PODHALER®", "type": "DRUG" }, { "name": "TOBI®", "type": "DRUG" }, { "name": "Bethkis®", "type": "DRUG" }, { "name": "Cayston®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 409, "start_date": "2015-05-05", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2022-03-22", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 47, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Bellflower, California + 43 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02449031" }, { "nct_id": "NCT02734537", "title": "Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant", "Lip and Oral Cavity Squamous Cell Carcinoma", "p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oral Cavity Verrucous Carcinoma", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oral Cavity Verrucous Carcinoma", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 189, "start_date": "2016-11-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 679, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 450 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02734537" }, { "nct_id": "NCT01479465", "title": "Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Simtuzumab", "type": "BIOLOGICAL" }, { "name": "Placebo to match SIM", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 266, "start_date": "2011-12", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2019-04-17", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 56, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479465" }, { "nct_id": "NCT03464565", "title": "COMPLETE: International Acute Ischemic Stroke Registry With the Penumbra System Aspiration Including the 3D Revascularization Device", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stroke, Ischemic" ], "interventions": [ { "name": "Penumbra System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Penumbra Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 650, "start_date": "2018-07-02", "completion_date": "2020-01-17", "has_results": false, "last_update_posted_date": "2020-12-22", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 29, "location_summary": "Mesa, Arizona • Castro Valley, California • Fullerton, California + 25 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Castro Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03464565" }, { "nct_id": "NCT02224781", "title": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Recurrent Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2015-09-08", "completion_date": "2026-12-19", "has_results": true, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-05T11:26:01.986Z", "location_count": 838, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02224781" } ] }